Colloidal gold: a novel nanoparticle for targeted cancer therapeutics.

Anathea C. Powell, Giulio F. Paciotti, Steven K. Libutti

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Since their initial description in 1857, gold nanoparticles have been used extensively in the fields of diagnostics and therapeutics. Now, gold nanoparticles are engineered to target the delivery of potent anti-cancer therapeutics to solid tumors to improve either their safety or efficacy or both. Described in this chapter is the development of one such nanotherapeutic, termed CYT-6091, that targets the delivery of tumor necrosis factor alpha (TNF) to solid tumors. Outlined in the presentation is a discussion of nanoparticles and specifically colloidal gold, an historical review on the biology of TNF and its limited use in the clinic when administered systemically, and finally, how gold nanoparticles bound with TNF may improve the safety and efficacy profiles of TNF.

Original languageEnglish (US)
Pages (from-to)375-384
Number of pages10
JournalMethods in molecular biology (Clifton, N.J.)
Volume624
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Gold Colloid
Nanoparticles
Tumor Necrosis Factor-alpha
Gold
Neoplasms
Safety
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Colloidal gold : a novel nanoparticle for targeted cancer therapeutics. / Powell, Anathea C.; Paciotti, Giulio F.; Libutti, Steven K.

In: Methods in molecular biology (Clifton, N.J.), Vol. 624, 2010, p. 375-384.

Research output: Contribution to journalArticle

Powell, Anathea C. ; Paciotti, Giulio F. ; Libutti, Steven K. / Colloidal gold : a novel nanoparticle for targeted cancer therapeutics. In: Methods in molecular biology (Clifton, N.J.). 2010 ; Vol. 624. pp. 375-384.
@article{202bbe704e504c6392910fea4ca56ce1,
title = "Colloidal gold: a novel nanoparticle for targeted cancer therapeutics.",
abstract = "Since their initial description in 1857, gold nanoparticles have been used extensively in the fields of diagnostics and therapeutics. Now, gold nanoparticles are engineered to target the delivery of potent anti-cancer therapeutics to solid tumors to improve either their safety or efficacy or both. Described in this chapter is the development of one such nanotherapeutic, termed CYT-6091, that targets the delivery of tumor necrosis factor alpha (TNF) to solid tumors. Outlined in the presentation is a discussion of nanoparticles and specifically colloidal gold, an historical review on the biology of TNF and its limited use in the clinic when administered systemically, and finally, how gold nanoparticles bound with TNF may improve the safety and efficacy profiles of TNF.",
author = "Powell, {Anathea C.} and Paciotti, {Giulio F.} and Libutti, {Steven K.}",
year = "2010",
doi = "10.1007/978-1-60761-609-2_25",
language = "English (US)",
volume = "624",
pages = "375--384",
journal = "Methods in Molecular Biology",
issn = "1064-3745",
publisher = "Humana Press",

}

TY - JOUR

T1 - Colloidal gold

T2 - a novel nanoparticle for targeted cancer therapeutics.

AU - Powell, Anathea C.

AU - Paciotti, Giulio F.

AU - Libutti, Steven K.

PY - 2010

Y1 - 2010

N2 - Since their initial description in 1857, gold nanoparticles have been used extensively in the fields of diagnostics and therapeutics. Now, gold nanoparticles are engineered to target the delivery of potent anti-cancer therapeutics to solid tumors to improve either their safety or efficacy or both. Described in this chapter is the development of one such nanotherapeutic, termed CYT-6091, that targets the delivery of tumor necrosis factor alpha (TNF) to solid tumors. Outlined in the presentation is a discussion of nanoparticles and specifically colloidal gold, an historical review on the biology of TNF and its limited use in the clinic when administered systemically, and finally, how gold nanoparticles bound with TNF may improve the safety and efficacy profiles of TNF.

AB - Since their initial description in 1857, gold nanoparticles have been used extensively in the fields of diagnostics and therapeutics. Now, gold nanoparticles are engineered to target the delivery of potent anti-cancer therapeutics to solid tumors to improve either their safety or efficacy or both. Described in this chapter is the development of one such nanotherapeutic, termed CYT-6091, that targets the delivery of tumor necrosis factor alpha (TNF) to solid tumors. Outlined in the presentation is a discussion of nanoparticles and specifically colloidal gold, an historical review on the biology of TNF and its limited use in the clinic when administered systemically, and finally, how gold nanoparticles bound with TNF may improve the safety and efficacy profiles of TNF.

UR - http://www.scopus.com/inward/record.url?scp=77953466025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953466025&partnerID=8YFLogxK

U2 - 10.1007/978-1-60761-609-2_25

DO - 10.1007/978-1-60761-609-2_25

M3 - Article

C2 - 20217609

AN - SCOPUS:77953466025

VL - 624

SP - 375

EP - 384

JO - Methods in Molecular Biology

JF - Methods in Molecular Biology

SN - 1064-3745

ER -